vs
EXACT SCIENCES CORP（EXAS）与INNOSPEC INC.（IOSP）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是INNOSPEC INC.的1.9倍（$878.4M vs $453.2M），INNOSPEC INC.净利率更高（6.8% vs -9.8%，领先16.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 2.8%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 2.1%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Innospec Inc.是一家美国特种化学品企业，前身为奥克泰尔公司及联合奥克泰尔有限公司，旗下设有三大业务板块：高性能化学品业务覆盖个人护理、家居护理、农化、采矿及工业市场；燃料特种化学品业务专注于生产和供应燃油添加剂；油田服务业务则提供钻井、完井及采油相关化学品。
EXAS vs IOSP — 直观对比
营收规模更大
EXAS
是对方的1.9倍
$453.2M
营收增速更快
EXAS
高出20.3%
2.8%
净利率更高
IOSP
高出16.6%
-9.8%
两年增速更快
EXAS
近两年复合增速
2.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $453.2M |
| 净利润 | $-86.0M | $30.8M |
| 毛利率 | 70.1% | 27.3% |
| 营业利润率 | -9.4% | 8.1% |
| 净利率 | -9.8% | 6.8% |
| 营收同比 | 23.1% | 2.8% |
| 净利润同比 | 90.1% | -8.3% |
| 每股收益（稀释后） | $-0.45 | $1.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASIOSP
| Q1 26 | — | $453.2M | ||
| Q4 25 | $878.4M | $455.6M | ||
| Q3 25 | $850.7M | $441.9M | ||
| Q2 25 | $811.1M | $439.7M | ||
| Q1 25 | $706.8M | $440.8M | ||
| Q4 24 | $713.4M | $466.8M | ||
| Q3 24 | $708.7M | $443.4M | ||
| Q2 24 | $699.3M | $435.0M |
净利润EXASIOSP
| Q1 26 | — | $30.8M | ||
| Q4 25 | $-86.0M | $47.4M | ||
| Q3 25 | $-19.6M | $12.9M | ||
| Q2 25 | $-1.2M | $23.5M | ||
| Q1 25 | $-101.2M | $32.8M | ||
| Q4 24 | $-864.6M | $-70.4M | ||
| Q3 24 | $-38.2M | $33.4M | ||
| Q2 24 | $-15.8M | $31.2M |
毛利率EXASIOSP
| Q1 26 | — | 27.3% | ||
| Q4 25 | 70.1% | 28.0% | ||
| Q3 25 | 68.6% | 26.4% | ||
| Q2 25 | 69.3% | 28.0% | ||
| Q1 25 | 70.8% | 28.4% | ||
| Q4 24 | 69.0% | 29.2% | ||
| Q3 24 | 69.4% | 28.0% | ||
| Q2 24 | 69.8% | 29.2% |
营业利润率EXASIOSP
| Q1 26 | — | 8.1% | ||
| Q4 25 | -9.4% | 10.3% | ||
| Q3 25 | -3.0% | 1.3% | ||
| Q2 25 | -0.3% | 7.8% | ||
| Q1 25 | -13.6% | 9.6% | ||
| Q4 24 | -122.8% | 8.8% | ||
| Q3 24 | -5.6% | 10.3% | ||
| Q2 24 | -3.8% | 9.4% |
净利率EXASIOSP
| Q1 26 | — | 6.8% | ||
| Q4 25 | -9.8% | 10.4% | ||
| Q3 25 | -2.3% | 2.9% | ||
| Q2 25 | -0.1% | 5.3% | ||
| Q1 25 | -14.3% | 7.4% | ||
| Q4 24 | -121.2% | -15.1% | ||
| Q3 24 | -5.4% | 7.5% | ||
| Q2 24 | -2.3% | 7.2% |
每股收益（稀释后）EXASIOSP
| Q1 26 | — | $1.22 | ||
| Q4 25 | $-0.45 | $1.90 | ||
| Q3 25 | $-0.10 | $0.52 | ||
| Q2 25 | $-0.01 | $0.94 | ||
| Q1 25 | $-0.54 | $1.31 | ||
| Q4 24 | $-4.69 | $-2.80 | ||
| Q3 24 | $-0.21 | $1.33 | ||
| Q2 24 | $-0.09 | $1.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $289.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.4B |
| 总资产 | $5.9B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASIOSP
| Q1 26 | — | $289.1M | ||
| Q4 25 | $964.7M | $292.5M | ||
| Q3 25 | $1.0B | $270.8M | ||
| Q2 25 | $858.4M | $266.6M | ||
| Q1 25 | $786.2M | $299.8M | ||
| Q4 24 | $1.0B | $289.2M | ||
| Q3 24 | $1.0B | $303.8M | ||
| Q2 24 | $946.8M | $240.2M |
股东权益EXASIOSP
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $3.2B | $1.2B | ||
| Q2 24 | $3.2B | $1.2B |
总资产EXASIOSP
| Q1 26 | — | $1.8B | ||
| Q4 25 | $5.9B | $1.8B | ||
| Q3 25 | $5.9B | $1.8B | ||
| Q2 25 | $5.8B | $1.8B | ||
| Q1 25 | $5.7B | $1.8B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $6.7B | $1.8B | ||
| Q2 24 | $6.7B | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $17.6M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | 2.0% |
| 现金转化率经营现金流/净利润 | — | 0.57× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASIOSP
| Q1 26 | — | $17.6M | ||
| Q4 25 | $151.7M | $61.4M | ||
| Q3 25 | $219.9M | $39.3M | ||
| Q2 25 | $89.0M | $9.3M | ||
| Q1 25 | $30.8M | $28.3M | ||
| Q4 24 | $47.1M | $25.7M | ||
| Q3 24 | $138.7M | $73.5M | ||
| Q2 24 | $107.1M | $4.7M |
自由现金流EXASIOSP
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $46.8M | ||
| Q3 25 | $190.0M | $25.0M | ||
| Q2 25 | $46.7M | $-3.7M | ||
| Q1 25 | $-365.0K | $19.9M | ||
| Q4 24 | $10.7M | $13.6M | ||
| Q3 24 | $112.6M | $65.8M | ||
| Q2 24 | $71.2M | $-6.2M |
自由现金流率EXASIOSP
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 10.3% | ||
| Q3 25 | 22.3% | 5.7% | ||
| Q2 25 | 5.8% | -0.8% | ||
| Q1 25 | -0.1% | 4.5% | ||
| Q4 24 | 1.5% | 2.9% | ||
| Q3 24 | 15.9% | 14.8% | ||
| Q2 24 | 10.2% | -1.4% |
资本支出强度EXASIOSP
| Q1 26 | — | 2.0% | ||
| Q4 25 | 3.6% | 3.2% | ||
| Q3 25 | 3.5% | 3.2% | ||
| Q2 25 | 5.2% | 3.0% | ||
| Q1 25 | 4.4% | 1.9% | ||
| Q4 24 | 5.1% | 2.6% | ||
| Q3 24 | 3.7% | 1.7% | ||
| Q2 24 | 5.1% | 2.5% |
现金转化率EXASIOSP
| Q1 26 | — | 0.57× | ||
| Q4 25 | — | 1.30× | ||
| Q3 25 | — | 3.05× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.20× | ||
| Q2 24 | — | 0.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
IOSP
暂无分部数据
